Minerva Neurosciences | NERV - Passività Correnti





Passività Correnti Cambiamento Data
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Adma Biologics USD 69.54M 13.05M 2025-12
ALKERMES USD 599.5M 56.06M 2026-03
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
AstraZeneca USD 32.57B 1.95B 2026-03
BioCryst Pharmaceuticals USD 196.07M 5.83M 2025-12
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Cipla INR 62.97B 8.13B 2025-09
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 22.57M 2.29M 2025-12
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.81M 58.22M 2025-12
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Grifols EUR 2.37B 156.97M 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Ionis Pharmaceuticals USD 717M 66M 2026-03
J&J USD 57.72B 3.59B 2026-03
Merck USD 26.94B 1.38B 2026-03
Minerva Neurosciences USD 2.29M 381K 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Novavax USD 342.46M 117.49M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 30.01B 1.66B 2026-03
Takeda JPY 2.61T 470.53B 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12